Valsts: Dienvidāfrikas Republika
Valoda: angļu
Klimata pārmaiņas: South African Health Products Regulatory Authority (SAHPRA)
Bayer
AVELON Tablets AVELON IV Solution for Infusion PMR 01143137 and PMR 01158983 SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): AVELON Tablets AVELON IV Solution for Infusion COMPOSITION: Avelon film coated tablet contains moxifloxacin hydrochloride equivalent to 400 mg moxifloxacin. A single sterile unit of Avelon IV 250 mL infusion solution contains moxifloxacin hydrochloride equivalent to 400 mg moxifloxacin. PHARMACOLOGICAL CLASSIFICATION: A. 20.1.1 Broad and medium spectrum antibiotic PHARMACOLOGICAL ACTION: Moxifloxacin is a fluoroquinolone antibacterial with a broad spectrum of bactericidal action. Moxifloxacin has been shown to be active against most of the following microorganisms in vitro. In-vitro sensitivity may not always have been confirmed in clinical infection (see Indications). MICROBIOLOGY Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative microorganisms. The bactericidal action of moxifloxacin results from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase IV required for bacterial DNA replication, transcription, repair, and recombination. It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety. The mechanism of action for quinolones, including moxifloxacin, is different from that of macrolides, beta-lactams, aminoglycosides, or tetracyclines; therefore, microorganisms resistant to these classes of drugs may be susceptible to moxifloxacin and other quinolones. There is no known cross-resistance between moxifloxacin and other classes of antimicrobials. Cross-resistance has been observed between moxifloxacin and other fluoroquinolones against Gram-negative bacteria. Gram-positive bacteria resistant to other fluoroquinolon Izlasiet visu dokumentu